Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Dianthus Therapeutics, Inc. /DE/
Report date December 02, 2019 · Filed December 03, 2019
Section 16 reporting ended · disclosed 2019-12-03. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| common stockSEC Table I · non-derivative | Direct | 240,523 |
Ending reported balance
After 2019-12-02 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2019-12-02 · Sale · Disposed 3,627 · Balance 244,396 F1: This transaction was executed in multiple trades at prices ranging from $12.25 to $13.20. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request by the staff of the U.S. Securities and Exchange Commission, the issuer or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. Row 2 · 2019-12-02 · Sale · Disposed 1,373 · Balance 243,023 F2: This transaction was executed in multiple trades at prices ranging from $13.25 to $13.39. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request by the staff of the U.S. Securities and Exchange Commission, the issuer or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. Row 3 · 2019-12-02 · Sale · Disposed 2,500 · Balance 240,523 F3: This transaction was executed in multiple trades at prices ranging from $12.75 to $13.35. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request by the staff of the U.S. Securities and Exchange Commission, the issuer or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was executed in multiple trades at prices ranging from $12.25 to $13.20. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request by the staff of the U.S. Securities and Exchange Commission, the issuer or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected.
F2: This transaction was executed in multiple trades at prices ranging from $13.25 to $13.39. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request by the staff of the U.S. Securities and Exchange Commission, the issuer or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected.
F3: This transaction was executed in multiple trades at prices ranging from $12.75 to $13.35. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request by the staff of the U.S. Securities and Exchange Commission, the issuer or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 02, 2019 Filed Dec 3, 2019 01:29 UTC | Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 | Salecommon stock | 2,500 | $13.21 | $33,036.00 |
DisclosureSEC source: 0001562180-19-005782 · primarydocument.xml · nonDerivative · entry 3 COOKE MICHAEL P. · CIK 0001741288 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 240,523 F3 · price: This transaction was executed in multiple trades at prices ranging from $12.75 to $13.35. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request by the staff of the U.S. Securities and Exchange Commission, the issuer or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 02, 2019 Filed Dec 3, 2019 01:29 UTC | Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 | Salecommon stock | 1,373 | $13.31 | $18,279.30 |
DisclosureSEC source: 0001562180-19-005782 · primarydocument.xml · nonDerivative · entry 2 COOKE MICHAEL P. · CIK 0001741288 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 243,023 F2 · price: This transaction was executed in multiple trades at prices ranging from $13.25 to $13.39. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request by the staff of the U.S. Securities and Exchange Commission, the issuer or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 02, 2019 Filed Dec 3, 2019 01:29 UTC | Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 | Salecommon stock | 3,627 | $12.74 | $46,204.72 |
DisclosureSEC source: 0001562180-19-005782 · primarydocument.xml · nonDerivative · entry 1 COOKE MICHAEL P. · CIK 0001741288 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 244,396 F1 · price: This transaction was executed in multiple trades at prices ranging from $12.25 to $13.20. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request by the staff of the U.S. Securities and Exchange Commission, the issuer or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 20, 2019 Filed Nov 26, 2019 01:52 UTC | Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 | Salecommon stock | 5,000 | $12.00 | $60,000.00 |
DisclosureSEC source: 0001562180-19-005711 · primarydocument.xml · nonDerivative · entry 1 COOKE MICHAEL P. · CIK 0001741288 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 248,023 Read SEC document |
| November 01, 2019 Filed Nov 2, 2019 00:02 UTC | Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 | Salecommon stock | 5,000 | $10.67 | $53,333.50 |
DisclosureSEC source: 0001562180-19-005307 · primarydocument.xml · nonDerivative · entry 1 COOKE MICHAEL P. · CIK 0001741288 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 253,023 F1 · price: This transaction was executed in multiple trades at prices ranging from $10.35 to $10.715. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request by the staff of the U.S. Securities and Exchange Commission, the issuer or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 01, 2019 Filed Oct 3, 2019 20:50 UTC | Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 | SaleCommon Stock | 5,000 | $10.01 | $50,064.00 |
DisclosureSEC source: 0001562180-19-005101 · primarydocument.xml · nonDerivative · entry 1 COOKE MICHAEL P. · CIK 0001741288 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 258,023 F1 · price: This transaction was executed in multiple trades at prices ranging from $9.515 to $10.22. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request by the staff of the U.S. Securities and Exchange Commission, the issuer or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 19, 2019 Filed Sep 19, 2019 20:26 UTC | Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 | Salecommon stock | 1,656 | $12.00 | $19,872.00 |
DisclosureSEC source: 0001562180-19-004884 · primarydocument.xml · nonDerivative · entry 1 COOKE MICHAEL P. · CIK 0001741288 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 263,023 F1 · kind: This trade is pursuant to an active 10b5-1 plan. Read SEC document |
| September 12, 2019 Filed Sep 16, 2019 22:36 UTC | Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 | Salecommon stock | 844 | $12.00 | $10,128.00 |
DisclosureSEC source: 0001562180-19-004830 · primarydocument.xml · nonDerivative · entry 1 COOKE MICHAEL P. · CIK 0001741288 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 264,679 F1 · kind: This trade is pursuant to an active 10b5-1 plan. Read SEC document |
| September 03, 2019 Filed Sep 4, 2019 21:06 UTC | Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 | SaleCommon Stock | 5,000 | $10.11 | $50,531.00 |
DisclosureSEC source: 0001562180-19-004630 · primarydocument.xml · nonDerivative · entry 1 COOKE MICHAEL P. · CIK 0001741288 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 265,523 F1 · kind: This trade is pursuant to an active 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $9.81 to $10.225. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request by the staff of the U.S. Securities and Exchange Commission, the issuer or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 01, 2019 Filed Aug 1, 2019 20:14 UTC | Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 | Salecommon stock | 2,500 | $13.41 | $33,522.50 |
DisclosureSEC source: 0001562180-19-004122 · primarydocument.xml · nonDerivative · entry 2 COOKE MICHAEL P. · CIK 0001741288 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 270,523 F1 · kind: This trade is pursuant to an active 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $13.40 to $13.4325. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request by the staff of the U.S. Securities and Exchange Commission, the issuer or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 01, 2019 Filed Aug 1, 2019 20:14 UTC | Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 | Salecommon stock | 5,000 | $13.42 | $67,108.50 |
DisclosureSEC source: 0001562180-19-004122 · primarydocument.xml · nonDerivative · entry 1 COOKE MICHAEL P. · CIK 0001741288 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 273,023 F1 · kind: This trade is pursuant to an active 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $13.40 to $13.4325. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request by the staff of the U.S. Securities and Exchange Commission, the issuer or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 01, 2019 Filed Jul 2, 2019 14:51 UTC | Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 | Salecommon stock | 2,500 | $14.42 | $36,050.50 |
DisclosureSEC source: 0001562180-19-003734 · primarydocument.xml · nonDerivative · entry 2 COOKE MICHAEL P. · CIK 0001741288 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 278,023 F1 · kind: This trade is pursuant to an active 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $14.20 to $14.80. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request by the staff of the U.S. Securities and Exchange Commission, the issuer or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 01, 2019 Filed Jul 2, 2019 14:51 UTC | Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 | Salecommon stock | 5,000 | $14.39 | $71,932.50 |
DisclosureSEC source: 0001562180-19-003734 · primarydocument.xml · nonDerivative · entry 1 COOKE MICHAEL P. · CIK 0001741288 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 280,523 F1 · kind: This trade is pursuant to an active 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $14.20 to $14.80. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request by the staff of the U.S. Securities and Exchange Commission, the issuer or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 17, 2019 Filed Jun 18, 2019 21:18 UTC | Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 | Salecommon stock | 7,500 | $13.90 | $104,267.25 |
DisclosureSEC source: 0001562180-19-003585 · primarydocument.xml · nonDerivative · entry 1 COOKE MICHAEL P. · CIK 0001741288 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 285,523 F1 · kind: This trade is pursuant to an active 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $13.72 to $14.20. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 05, 2019 Filed Feb 7, 2019 21:19 UTC | Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 | GrantStock Option (Right to Buy) · Derivative | 64,000 | $0.00 Strike: $7.13 | $0.00 |
DisclosureSEC source: 0000899243-19-002870 · doc4.xml · derivative · entry 1 COOKE MICHAEL P. · CIK 0001741288 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,000 Underlying: Common Stock · 64,000 shares Expires 2029-02-04 F1 · derivative.exercise_date: This option shall vest and become exercisable in 12 equal quarterly installments beginning on January 1, 2019. Read SEC document |
| June 25, 2018 Filed Jun 27, 2018 20:30 UTC | Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 | ConversionSeries B Preferred Stock · Derivative | 1,287 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-018333 · doc4.xml · derivative · entry 3 COOKE MICHAEL P. · CIK 0001741288 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 498 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series A Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date. F1 · price: The Series A Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: The Series A Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: The Series A Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date. Read SEC document |
| June 25, 2018 Filed Jun 27, 2018 20:30 UTC | Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 | ConversionSeries A Preferred Stock · Derivative | 10,005 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-018333 · doc4.xml · derivative · entry 2 COOKE MICHAEL P. · CIK 0001741288 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,872 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series A Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date. F1 · price: The Series A Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: The Series A Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: The Series A Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date. Read SEC document |
| June 25, 2018 Filed Jun 27, 2018 20:30 UTC | Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 | ConversionCommon Stock | 4,370 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-018333 · doc4.xml · nonDerivative · entry 1 COOKE MICHAEL P. · CIK 0001741288 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 293,023 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series A Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.